| Therapeutic | Obinutuzumab |
| Target | MS4A1 |
| Heavy Chain | QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS |
| Light Chain | DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK |
| 100% seqID Fv Structure | 3pp3%3AHL%3AIK%2F3pp4%3AHL [Fvs: ] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 3pp3%3AHL%3AIK%2F3pp4%3AHL [Fvs: ] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (August '23) | Approved |
| Estimated Status (August '23) | Active |
| Recorded Developmental Technology | GlycoMAb Technology |
| INN Year Proposed | 2008 |
| INN Year Recommended | 2011 |
| Companies Involved | GLYCART Biotechnology%3BBiogen Idec%3BChugai Pharmaceutical%3BDana-Farber Cancer Institute%3BGenentech%3BLymphoma Academic Research Organisation%3BNippon Shinyaku%3BOHSU Knight Cancer Institute%3BPharmacyclics%3BPolish Myeloma Consortium%3BRoche%3BThomas Jefferson University%3BUniversity of Heidelberg%3BUniversity of Leeds |
| Conditions Approved | Chronic lymphocytic leukaemia%3BFollicular lymphoma%3BNon-Hodgkin%27s lymphoma |
| Conditions Active | Diffuse large B cell lymphoma%3BCNS cancer%3BGraft-versus-host disease%3BLupus nephritis%3BMantle-cell lymphoma%3BWaldenstrom%27s macroglobulinaemia |
| Conditions Discontinued | Primary biliary cirrhosis |
| Notes | Obinutuzumab and Afutuzumab are the same mAb |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
